WallStSmart

Auna S.A. (AUNA)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 1382% more annual revenue ($65.01B vs $4.39B). MRK leads profitability with a 28.1% profit margin vs 2.2%. AUNA trades at a lower P/E of 13.7x. MRK earns a higher WallStSmart Score of 59/100 (C).

AUNA

Hold

48

out of 100

Grade: D+

Growth: 5.3Profit: 5.0Value: 6.0Quality: 3.0
Piotroski: 4/9Altman Z: 0.92

MRK

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 9.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AUNA.

MRKOvervalued (-13.2%)

Margin of Safety

-13.2%

Fair Value

$96.48

Current Price

$109.18

$12.70 premium

UndervaluedFair: $96.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AUNA2 strengths · Avg: 9.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

P/E RatioValuation
13.7x8/10

Attractively priced relative to earnings

MRK6 strengths · Avg: 9.2/10
Market CapQuality
$274.03B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
32.8%10/10

Strong operational efficiency at 32.8%

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

Areas to Watch

AUNA4 concerns · Avg: 2.8/10
Market CapQuality
$375.47M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
6.5%3/10

ROE of 6.5% — below average capital efficiency

Profit MarginProfitability
2.2%3/10

2.2% margin — thin

EPS GrowthGrowth
-50.9%2/10

Earnings declined 50.9%

MRK3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.362/10

Expensive relative to growth rate

EPS GrowthGrowth
-19.3%2/10

Earnings declined 19.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : AUNA

The strongest argument for AUNA centers on Price/Book, P/E Ratio.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.

Bear Case : AUNA

The primary concerns for AUNA are Market Cap, Return on Equity, Profit Margin. Debt-to-equity of 2.23 is elevated, increasing financial risk. Thin 2.2% margins leave little buffer for downturns.

Bear Case : MRK

The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

AUNA carries more volatility with a beta of 1.64 — expect wider price swings.

AUNA is growing revenue faster at 6.5% — sustainability is the question.

MRK generates stronger free cash flow (1.8B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (59/100 vs 48/100), backed by strong 28.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Auna S.A.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Auna S.A. is a prominent telecommunications and digital services provider in Latin America, specializing in integrated solutions that enhance connectivity and customer experience. With a comprehensive portfolio that includes high-speed internet, television, and mobile services, Auna caters to both residential and business clients across a variety of markets. The company's dedication to innovation and exceptional customer service has established it as a key player in the region's dynamic digital landscape. Its extensive and robust infrastructure positions Auna favorably to leverage the growing demand for advanced telecom solutions, presenting significant growth opportunities for institutional investors.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?